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Roles of anaerobic bacteria in morbid conditions
of respiratory infections
Many anaerobic bacteria are resident ﬂora of the upper
airway and oral cavity. It is easily understood that
anaerobic bacteria are major contributors to morbid con-
ditions of respiratory infections, the occurrence of which
involves the inter-relation between the upper and lower
airways. The frequency of anaerobe isolation in respira-
tory infections reportedly accounts for 8–16% [1], and
bacteria are particularly involved in aspiration pneumonia,
necrotic pneumonia, lung abscess and pyothorax. With
regard to the frequency of anaerobic bacteria detection in
various types of respiratory infections, however, anaerobe
detection in acute bronchitis is second to that of Hae-
mophilus inﬂuenzae, a-hemolytic Streptococcus, Strepto-
coccus pneumoniae (pneumococci), Moraxella catarrhalis
and Staphylococcus aureus. Anaerobes are mostly detec-
ted at the same frequency as M. catarrhalis and S. aureus
(Fig. 1). The frequencies of H. inﬂuenzae and Pseudo-
monas aeruginosa detection in the stable stage of chronic
lower airway infection are highest, that for anaerobes low.
By contrast, at the time of acute exacerbation of chronic
lower airway infection the frequency of anaerobe detec-
tion is second to that for H. inﬂuenzae, pneumococci and
P. aeruginosa, being higher than that for M. catarrhalis
(Figs. 2, 3). The frequency of anaerobe detection in nos-
ocomial pneumonia was second to that for a-hemolytic
Streptococcus, followed by those for P. aeruginosa and
then S. aureus. In contrast, the frequency of detecting
pneumococci in community-acquired pneumonia is high-
est, followed by a-hemolytic Streptococcus, H. inﬂuenzae,
M. catarrhalis, S. aureus and ﬁnally anaerobic bacteria.
Thus, anaerobic bacteria are detected at mostly the same
frequency as M. catarrhalis and S. aureus in community-
acquired pneumonia, though the frequency is not as high
as that in nosocomial pneumonia (Figs. 4, 5). Anaerobic
bacteria are involved in all morbid conditions of respira-
tory infections, and the frequencies of isolation are high
in pneumonia and at the time of acute exacerbation
of chronic lower airway infection. As for detection
of anaerobes in other infections, they are detected in 93%
of lung abscess and 54% of pyothorax cases. Thus,
anaerobic bacteria should not be neglected, because the
frequency of their detection varies considerably among
morbid conditions, and anaerobic bacteria do not merely
drift down from the upper airway but also show major
involvement in morbid conditions. It should be recognized
that anaerobic bacteria are extensively involved not only
in lung abscess and aspiration pneumonia, in which
anaerobic infection has conventionally been indicated to
participate, but also pneumonia and acute exacerbation of
chronic lower airway infection.
Causative bacteria
Anaerobic bacteria isolated from respiratory infections
include Peptostreptococcus, Prevotella melaninogenica,
Veillonella parvula and Prevotella intermedia (Table 1).
However, the majority of cases have polymicrobial
infections; the incidence of mixed infection particularly
with aerobic bacteria is as high as 75%. The amounts of
aerobic isolates are large at the time of acute exacerba-
tion of chronic lower airway infection, while the
amounts of anaerobic isolates are equal to or larger than
those for aerobic bacteria in lung abscesses and
pneumonia.
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Anaerobic respiratory infection risk factors
Many patients with anaerobic respiratory infections
(97.6%) have underlying diseases. The underlying diseases
other than a distinct episode of aspiration include dental
and periodontal diseases, diabetes mellitus (DM) and
chronic respiratory diseases [chronic lower airway infec-
tion, lung cancer, and chronic obstructive pulmonary
disease (COPD), etc.]. The prevalences of dental and
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Fig. 4 The bacteria detected in nosocomial pneumonia by TTA
(n = 169)
Table 1 Main bacteria detected in anaerobic respiratory infections
Total (n = 61)
Parvimonas micra 12
Prevotella melaninogenica 12
Fusobacterium species 6
Veillonella parvula 6
Prevotella intermedia 5
Peptostreptococcus species 5
Biﬁdobacterium species 4
Prevotella denticola 3
Peptococcus species 2
Others 6
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Fig. 1 The bacteria detected in acute bronchitis by transtracheal
aspiration (TTA) (n = 220)
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periodontal diseases are high in patients with anaerobic
isolates, and the bacteria reportedly correlate with anaer-
obic respiratory infections. Lifestyle factors such as heavy
smoking with a Brinkman index (B.I.) of at least 1,000 and
heavy alcohol consumption are also risk factors. There are
in addition systemic and regional factors, other than aspi-
ration, underlying the occurrence of anaerobic respiratory
infections, i.e., increased anaerobes in the upper airway and
oral cavity. Factors promoting the occurrence of anaerobic
respiratory infections include decreased defensive capacity
and an impaired ability of the entire body to defend against
infection, as well as decreased clearance in regional sites of
the airway, which accelerates bacterial invasion and growth
(Fig. 6). The incidence of respiratory infections related to
aspiration is considered to be likely to increase in the future
as the Japanese population ages. It is also necessary that
anaerobic respiratory infections be increasingly recognized
as important infections [2–4].
Diagnosis
Many anaerobic infection cases show polymicrobial
infections. They develop not only via mixing of multiple
anaerobic types but also mixing of anaerobic bacteria and
microaerophilic or facultative bacteria which exert syner-
gistic effects. Collection of appropriate test materials,
prompt transport of these materials to laboratories, and
appropriate treatment of the materials are necessary for
making the diagnosis of anaerobic infection. It is important
to collect test materials from the actual sites of infection by
a careful sampling method so to avoid contamination with
normal bacterial ﬂora. The test materials that merit anaer-
obic culture include specimens not contaminated with
indigenous bacterial ﬂora of the upper airway and oral
cavity, i.e., blood, pleural effusion, transtracheal aspiration
(TTA) materials, and those obtained by puncture and
aspiration from the abscess cavity or percutaneous lung
puncture. When any bacteria, conﬁrmable by gram stain-
ing, do not grow in the culture despite purulent good-
quality test materials, the involvement of anaerobes must
be suspected.
Clinical symptoms are cough, chest and back pain and
pyrexia of 38C or higher, but some patients are asymp-
tomatic. Malodorous sputum is a general sign, but is not
recognized in some patients. The presence of anaerobic
infection can barely be differentiated from any other bac-
terial infections based on clinical symptoms or ﬁndings in
patients with pneumonia or at the time of acute exacerba-
tion of chronic lower airway infection. Many lung abscess
lesions are located in the right superior, right inferior or left
superior lobe of the lung. Considerable attention should be
paid to making the diagnosis because of the absence of
pyrexia and low C-reactive protein (CRP) levels during the
course [4–6].
Antimicrobial therapy
The best selection of antibacterial drugs would be those with
antibacterial activity against both facultative and anaerobic
bacteria. The antibacterial drugs generally recommended for
treatment of anaerobic respiratory infections are b-lactams
with b-lactamase inhibitors, CLDM, cephamycins and
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Fig. 6 The onset mechanisms of anaerobic respiratory infections
Table 2 Resistance rates for clinically important anaerobic gram-negative rods against antimicrobial agents (modiﬁed from Ref. [2])
Virtual absence of resistance Low High Resistance
Metronidazolea Clindamycin Benzylpenicillin Aminoglycosides
Sulbactam/ampicillin Cefoxitin Cephalosporins Monobactams
Tazobactam/piperacillin Piperacillin Tetracycline Vancomycin
Carbapenems Cefmetazole Macrolides
Chloramphenicolb Fluoroquinolonesc
a This drug must be administered with antimicrobial agents that cover aerobic bacteria. Metronidazole shows no activity against gram-positive
non-spore-forming rods such as Actinomyces, Propionibacterium and Biﬁdobacterium
b Chloramphenicol may be less effective than other drugs
c Drugs excluding gatiﬂoxacin, moxiﬂoxacin and garenoxacin
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carbapenems (Table 2). Sulfamethoxazole-trimethoprim
(ST), aminoglycosides and monobactams are ineffective.
The rates for Peptostreptococcus and Fusobacterium with
b-lactamase production are low, while those for Prevotella
and Bacteroides are high. The drug resistance rates to ABPC
are high in Prevotella and Bacteroides, while the rate to
PIPC is moderate in Bacteroides. By contrast, the drug
resistance rates for all bacterial species with combinations of
these drugs, i.e., SBT/ABPC and TAZ/PIPC, are low
(Figs. 7, 8). With regard to cephems, the drug resistance rate
for each bacterial species to CAZ is relatively high, while
that to CMZ (a cephamycins) is as low as that to carba-
penems, showing the majority of strains to be sensitive
(Figs. 9, 10). On the other hand, each bacterial species
shows high resistance rates to TC and clarithromycin (CAM)
(Figs. 11, 12). Therefore, penicillins with b-lactamase
inhibitors are recommended for treatment of mild types of
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Fig. 7 Drug resistance rates to penicillins
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Fig. 8 Drug resistance rates to penicillins with b-lactamase inhibitors
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Fig. 9 Drug resistance rates to cephems
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Fig. 11 Drug resistance rates to tetracyclines (tetracycline)
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Fig. 12 Drug resistance rates to macrolides and clindamycin
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anaerobic respiratory infections, and penicillins with
b-lactamase inhibitors injections, cephamycins, and the
single use of carbapenems or combined use of carbapenems
with CLDM are recommended for moderate or more severe
anaerobic respiratory infections, taking into consideration
polymicrobial infections with aerobic bacteria. With regard
to the therapeutic effect, administration alleviates fever
in pneumonia and chronic lower airway infection with
3–4 days and in lung abscess with 5–6 days of treatment. In
the treatment of pyothorax, tube thoracostomy is used with
administration (Fig. 13) [6–9].
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Risk factors
Dental diseases, diabetes mellitus, chronic respiratory diseases (lung cancer, chronic 
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                      administration in the treatment of pyothorax.
Fig. 13 Diagnosing anaerobic respiratory infections and attitudes
toward treatment
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